articleTop 1% cited
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
The Lancet Oncology · 2019 · Vol. 20(7) · pp. 924–937
Howard WestMichael McCleod(Sarah Cannon)Maen Hussein(Sarah Cannon)Alessandro Morabito(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")Achim RittmeyerHenry Jacob Conter(William Osler Health System)Hans‐Georg Kopp(Robert Bosch (Germany))Davey B. Daniel(Tennessee Oncology)Steven McCune(Northwest Behavioral Medicine)Tarek Mekhail(Florida Hospital Cancer Institute)Alona Zer(Rabin Medical Center)Niels Reinmuth(Asklepios Fachkliniken München-Gauting)Ahad A. Sadiq(Fort Wayne Medical Institute)Alan SandlerWei Lin(Nektar Therapeutics (United States))Tania Ochi Lohmann(Roche (Switzerland))Venice Archer(Roche (United Kingdom))Lijia WangMarcin KowanetzFederico Cappuzzo✉(Azienda Unità Sanitaria Locale Della Romagna)
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsCancer Cells and MetastasisCarboplatinMedicinePaclitaxelAtezolizumabChemotherapyOncologyNab-paclitaxelOpen labelInternal medicineLung cancer
MeSH terms
AgedAged, 80 and overAlbuminsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleCarboplatinPaclitaxelAntibodies, Monoclonal, Humanized
Funding
- F. Hoffmann-La Roche
Citations
1,645
FWCI
84.77
field-weighted impact
References
22
Percentile
100%
vs. same field & year
Citations per year
Cited by
References
Oncology Meets Immunology: The Cancer-Immunity Cycle
Immunity · 2013 · 6,760 citations
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 9,391 citations
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2016 · 2,632 citations
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
The Lancet · 2015 · 6,477 citations
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2018 · 6,460 citations
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2018 · 2,268 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.